Raymond Prudo-Chlebosz

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
London
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Abizer Gaslightwala, as Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Raymond Prudo-Chlebosz

Form 4 holding Director

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
2,484,990
Estimated value
$2,783,189
Report date
20 Mar 2025
Price
$1.12
Ownership
Direct
Form 4 holding Director

Akari Therapeutics Plc

Security class
Series A Warrants (Right to Buy)
Shares / value
446,428
Estimated value
$499,999
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Series B Warrants (Right to Buy)
Shares / value
446,428
Estimated value
$499,999
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
400,383
Estimated value
$448,429
Report date
20 Mar 2025
Price
$1.12
Ownership
RPC Pharma Limited
Form 4 holding Director

Akari Therapeutics Plc

Security class
Pre-Funded Warrants to purchase ADRs
Shares / value
386,661
Estimated value
$156,249
Report date
16 Dec 2025
Price
$0.4041
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
19,355
Estimated value
$21,678
Report date
20 Mar 2025
Price
$1.12
Ownership
Praxis Trustees Limited
Form 4 holding Director

Akari Therapeutics Plc

Security class
Warrants to purchase American Depositary Shares ("ADRs")
Shares / value
618,658
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Warrants to purchase ADRs
Shares / value
386,661
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Stock Option (Right to Buy)
Shares / value
225,000
Estimated value
Report date
20 Mar 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount

Insider Reports Filed by Raymond Prudo-Chlebosz

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .